Does Evenity cause hair loss? This is a question raised by some postmenopausal women starting romosozumab (Evenity) for severe osteoporosis. Evenity is a monoclonal antibody that works by inhibiting sclerostin to stimulate bone formation and reduce bone resorption — a dual mechanism that sets it apart from other osteoporosis treatments. Based on the UK Summary of Product Characteristics and current clinical evidence, hair loss is not a recognised side effect of romosozumab. However, understanding the full side effect profile, why hair changes can occur during treatment, and when to seek medical advice is essential for anyone receiving this therapy.

Evenity and Hair Loss: What the Evidence Shows

Hair loss is not listed as a recognised side effect of Evenity (romosozumab) in the UK SmPC, and no established link between romosozumab and alopecia exists based on current clinical evidence.

Experiencing these side effects? Our pharmacists can help you navigate them →

Evenity (romosozumab) is a monoclonal antibody used to treat severe osteoporosis in postmenopausal women at high risk of fracture. It works by inhibiting sclerostin, a protein that suppresses bone formation, thereby both stimulating new bone formation and reducing bone resorption — a dual action that distinguishes it from most other osteoporosis treatments. Given that hair loss is a concern many patients raise when starting any new medicine, it is understandable that some people wonder whether Evenity may be responsible.

Based on current clinical evidence and the UK Summary of Product Characteristics (SmPC) for romosozumab, available via the MHRA and the Electronic Medicines Compendium (medicines.org.uk), hair loss (alopecia) is not listed as a recognised side effect of romosozumab. It does not appear in section 4.8 of the UK SmPC as an adverse reaction identified in clinical trials. Therefore, there is no established link between Evenity and hair loss at this time.

However, individual patient experiences can vary, and spontaneous reports of side effects not captured in clinical trials do occasionally emerge through post-marketing surveillance. If you have noticed increased hair shedding or thinning since starting Evenity, it is important not to dismiss this, but to discuss it with your prescribing clinician, who can help determine whether the medicine or another underlying cause is responsible.

Reported Side Effects of Evenity (Romosozumab)

Recognised side effects of Evenity include arthralgia, headache, injection site reactions, hypocalcaemia, osteonecrosis of the jaw, atypical femoral fractures, and serious cardiovascular events; hair loss is not among them.

Not sure if this is normal? Chat with one of our pharmacists →

Understanding the recognised side effect profile of Evenity helps patients and clinicians make informed decisions about treatment. The following information is drawn from the UK SmPC for romosozumab (Evenity) and NICE Technology Appraisal TA791, which covers the use of romosozumab for treating severe osteoporosis after the menopause in women at high risk of fracture.

Very common or common side effects include:

• Joint pain (arthralgia)

• Headache

• Injection site reactions (redness, pain, or swelling)

• Hypocalcaemia (low blood calcium) — patients should have pre-existing hypocalcaemia corrected before starting treatment; those with severe renal impairment require particular monitoring as they are at increased risk

Less common but clinically important side effects and precautions include:

• Hypersensitivity reactions, including rash or urticaria

• Osteonecrosis of the jaw (ONJ) — a rare but serious condition affecting the jawbone. Before starting Evenity, patients with poor dental health or who are due to have invasive dental procedures should have a dental assessment. Good oral hygiene should be maintained throughout treatment, and any jaw pain, swelling, or numbness should be reported to a clinician promptly

• Atypical femoral fractures (AFF) — unusual thigh bone fractures that have been reported rarely with romosozumab, as well as with long-term antiresorptive therapy. Any new or unusual thigh or groin pain during treatment should be assessed promptly

• Cardiovascular events — clinical trials noted a higher rate of serious cardiac events (such as myocardial infarction and stroke) in patients receiving romosozumab compared with alendronate. As a result, Evenity is contraindicated in patients who have had a myocardial infarction or stroke within the preceding year. This is reflected in the MHRA Drug Safety Update on romosozumab and cardiovascular risk

Hair loss does not feature among these documented adverse effects. Patients should always read the patient information leaflet supplied with their medication and report any new or unexpected symptoms to their healthcare provider promptly. The treatment course for Evenity is limited to 12 monthly injections (each consisting of two subcutaneous injections of 105 mg to deliver the 210 mg monthly dose), after which patients are typically transitioned to an antiresorptive therapy such as a bisphosphonate or denosumab, in line with NICE TA791.

Why Some Medicines Can Affect Hair Growth

Medicines can disrupt hair growth via anagen or telogen effluvium, but hair thinning during Evenity treatment is more likely related to postmenopausal hormonal changes or other medications than to romosozumab itself.

To understand why patients may query whether Evenity causes hair loss, it helps to appreciate how certain medicines can disrupt the normal hair growth cycle. Hair follicles are highly sensitive to physiological changes, including hormonal shifts, nutritional deficiencies, and systemic inflammation — all of which can be influenced by medications.

Some medicines directly interfere with the anagen (active growth) phase of the hair cycle, leading to a condition called anagen effluvium, which is typically associated with chemotherapy agents. Others trigger telogen effluvium, a more gradual shedding that occurs when a large number of hair follicles prematurely enter the resting phase. This can be caused by physiological stress, illness, or certain drugs including anticoagulants, retinoids, and some antihypertensives. It is worth noting that telogen effluvium can begin weeks to months after a triggering event, meaning hair loss noticed during Evenity treatment may in fact have been set in motion by an earlier cause.

Importantly, osteoporosis itself and the postmenopausal state — the population most likely to be prescribed Evenity — are associated with hormonal changes (particularly declining oestrogen levels) that can independently contribute to hair thinning. This means that hair loss experienced around the time of starting Evenity may well be coincidental rather than causally related to the medication.

Some other osteoporosis treatments have occasionally featured in post-marketing adverse drug reaction reports relating to hair changes; however, such reports are rare and the evidence linking them to hair loss is not well established. If hair loss is a concern, a thorough review of all current medications, nutritional status (including ferritin, thyroid function, and vitamin D levels), and hormonal factors is essential before attributing the symptom to any single drug. The NHS provides patient-facing guidance on the common causes of hair loss and when to seek help.

When to Speak to Your GP or Specialist

Contact your GP if you notice progressive hair shedding, signs of hypocalcaemia, jaw pain, unusual thigh pain, or any cardiovascular symptoms during Evenity treatment; do not stop treatment without medical advice.

Whilst hair loss is not a confirmed side effect of Evenity, any new or worsening symptom that develops during treatment warrants clinical attention. Knowing when to seek advice helps ensure patient safety and allows for timely investigation of any underlying cause.

You should contact your GP or specialist if you experience:

• Noticeable or progressive hair thinning or shedding that began after starting Evenity

• Muscle cramps, spasms, or tingling in the fingers or around the mouth, which may suggest hypocalcaemia (low blood calcium) and require prompt medical review

• Signs of a serious allergic reaction, such as facial swelling, difficulty breathing, or widespread rash

• Jaw pain, swelling, or numbness, which may indicate osteonecrosis of the jaw

• Unusual thigh or groin pain, which could suggest an atypical femoral fracture

• Chest pain, sudden weakness, or difficulty speaking — symptoms that may indicate a cardiovascular event and require immediate emergency care (call 999)

For hair loss specifically, your GP can assess possible causes and, if appropriate, refer you to a dermatologist for further evaluation. Blood tests to check thyroid function, full blood count, ferritin, and vitamin D are often the first step in investigating unexplained hair shedding. It is important not to stop Evenity without medical advice, as discontinuing osteoporosis treatment prematurely can significantly increase fracture risk. Your clinician will weigh the benefits and risks of continuing treatment based on your individual circumstances.

Managing Side Effects During Osteoporosis Treatment

Most patients tolerate Evenity's 12-month course well; managing side effects includes maintaining calcium and vitamin D intake, good dental hygiene, and ensuring adequate nutrition to support hair health during investigations.

Managing side effects effectively is key to maintaining adherence to osteoporosis treatment, which is essential for reducing fracture risk. Evenity is administered as two subcutaneous injections (each 105 mg) once a month by a healthcare professional, and most patients tolerate the 12-month treatment course well.

For injection site reactions, which are among the most commonly reported side effects, applying a cold compress before and after the injection can help reduce discomfort and localised swelling. Rotating injection sites is also recommended.

Calcium and vitamin D: Adequate calcium and vitamin D intake should be maintained throughout treatment. Your clinician may recommend supplements if dietary intake is insufficient. Patients with severe renal impairment should be monitored for hypocalcaemia as directed by the UK SmPC.

Dental health: To reduce the risk of osteonecrosis of the jaw, maintain good oral hygiene, attend routine dental check-ups, and inform your dentist that you are receiving Evenity before undergoing any invasive dental procedures.

If you are concerned about hair changes during treatment, the following general measures may be supportive whilst investigations are under way:

• Ensure adequate nutrition, particularly sufficient protein, iron, and zinc, which are important for healthy hair growth

• Avoid harsh hair treatments such as bleaching, tight hairstyles, or excessive heat styling, which can worsen fragile hair

• Discuss any supplements with your GP before starting them, as some can interact with medications or mask underlying deficiencies

For patients experiencing anxiety about side effects, open communication with the prescribing team is invaluable. Specialist nurses in metabolic bone disease or rheumatology can often provide additional support and reassurance. NICE TA791 supports the use of romosozumab in appropriate postmenopausal women with severe osteoporosis at high risk of fracture, and the clinical benefits in terms of fracture prevention are well established. Any decision to modify or discontinue treatment should always be made collaboratively between the patient and their clinical team.

MHRA Guidance and Reporting Suspected Side Effects

Suspected side effects from Evenity, including unexpected hair loss, should be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk; a confirmed causal link is not required to submit a report.

The MHRA is the UK regulatory authority responsible for monitoring the safety of medicines after they have been licensed. Post-marketing surveillance plays a crucial role in identifying adverse effects that may not have been apparent during clinical trials, particularly rare or delayed reactions.

The MHRA operates the Yellow Card scheme, which allows both healthcare professionals and patients to report suspected side effects from any medicine, including Evenity. Reports can be submitted online at yellowcard.mhra.gov.uk or via the Yellow Card app. You do not need to be certain that the medicine caused the side effect — a suspicion is sufficient to make a report. This system is vital for building a comprehensive safety picture of medicines in real-world use.

If you believe you have experienced hair loss or any other unexpected symptom in connection with Evenity, submitting a Yellow Card report contributes to national pharmacovigilance efforts and may help protect other patients in the future. Your report will be reviewed alongside other data to determine whether any regulatory action is needed.

The EMA also maintains a public database of adverse drug reactions called EudraVigilance, which provides transparency around reported side effects across Europe and can be used as a supplementary source of post-marketing safety information for romosozumab. Staying informed through trusted sources — including the NHS, NICE TA791, the UK SmPC (available at medicines.org.uk), and the MHRA — ensures that treatment decisions are based on the most current and reliable evidence available.

Frequently Asked Questions